Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS)

Acta Neurologica Scandinavica

Volumn 100, Issue 1, 1999, Pages 6-11

  Niebroj Dobosz, Irena ^a,b   Janik, P ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

ALS; Amino acids; CSF; Plasma

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID RECEPTOR AFFECTING AGENT; ASPARTIC ACID; GLUTAMIC ACID; GLYCINE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DERIVATIZATION; GUILLAIN BARRE SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MOTOR NEUROPATHY; NERVE CELL NECROSIS; SENSORIMOTOR NEUROPATHY;

EID: 0032973265     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1999.tb00717.x     Document Type: Article

References (52)

1. 1. Appel, SH. Excitotoxic neuronal death in amyotrophic lateral sclerosis. Trends Neurosci 1993;16:3-5.
2. 2. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol 1997; 244(suppl 2):S3-S14.
3. 3. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1988;24:446-9.
4. 4. Plaitakis A, Constantatakis E. Altered metabolism or excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis. Brain Res Bull 1993;30:381-6.
5. 5. Rothstein JD, Lee JM, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. New Engl J Med 1992;326:1464-8.
6. 6. Rothstein JD, van Kammen M, Levey AI, Martin L, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
7. 7. Miller RG, Moore D, Young LA at al., the WALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-8.
8. 8. The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis. Neurology 1993;43:2466-70.
9. 9. Askmart H, Aquilonius SM, Gilberg PG, Liedholm LJ, Stalberg E, Wuopio R. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1995;56:197-200.
10. 10. Eisen A, Stewart H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using Lamotrigine. Can J Neurol Sci 1993;20:297-301.
11. 11. Bensimon G, Lacomblez L, Meininger V, and the ALS/ Riluzole Study group. A controlled trial of Riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994;330:585-91.
12. 12. Lacomblez L, Bensimon G, Nigel Leigh P, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-31.
13. 13. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(suppl):96-107.
14. 14. Francis PT, Lowe SL. Determination of transmitter-and non-transmitter-related amino acids in human samples by high performance liquid chromatography. In: Holman RB, Cross AJ, Joseph MH, eds. High performance liquid chromatography in neuroscience research. IBRO: John Wiley & Sons, 1993;119-38.
15. 15. Lindroth P, Mopper K. High performance liquid chromatographic determination of subpicomole amounts of amino acids by precolumn fluorescence derivatization with o-phthalaldehyde. Anal Chem 1979;51:1667-74.
16. 16. Joseph MH, Davies P. Electrochemical activity of o-phthalaldehyde mercaptoethanol derivatives of amino acids: application to high-performance liquid chromatographic determination of amino acids in plasma and other biological materials. J Chromatogr 1983;227:125-36.
17. 17. Roth M. Fluorescence reaction for amino acids. Anal Chem 1971;43:880-2.
18. 18. Young AB, Penney JB, Dauth GW, Bromberg MB, Gilman S. Glutamate or aspartate as a possible neurotransmitter of the cerebral cortico-fugal fibers in the monkey. Neurology 1983;33:1513-16.
19. 19. Fagg GE, Foster AC. Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience 1993;9:701-19.
20. 20. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325:529-33.
21. 21. Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 1988;241:835-7.
22. 22. Mayer ML, Vyklicky L Jr, Clements J. Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature 1989;338:425-7.
23. 23. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990;28:3-8
24. 24. Young AB. What's the excitement about excitotoxic amino acids in ALS? Ann Neurol 1990;28:9-11.
25. 25. Roberts E, Chase TN, Tower DB. GABA in nervous system function. New York: Raven Press, 1976.
26. 26. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem 1984;42:1-11.
27. 27. Nichols DG, Sihra TS, Sanchez-Prieto J. Calcium-dependent and -independent release of glutamate from synaptosomes maintained by continuous fluorometry. J Neurochem 1987;49:50-7.
28. 28. Korf J, Venema K. Amino acids in the substantia nigra of rats with striatal lesions produced by kainate acid. J Neurochem 1983;40:1171-3.
29. 29. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-34.
30. 30. Manev H, Costa E, Wroblewski J, Guidatti A. Abusive stimulation of excitatory amino acid receptors: a strategy to limit neurotoxicity. FASEB J 1990;4:2789-97.
31. 31. Olney JW, Ho OL, Rhee V. Cytotoxic effects of acidic and sulfur containing amino acids on the infant mouse central nervous system. Exp Brain Res 1971;14:61-70.
32. 32. Coyle JT. Neurotoxic amino acids in human degenerative disorders. Trends Neurosci 1982;5:287-8.
33. 33. Spencer PS, Nunn PB, Hugon J et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987;237:517-22.
34. 34. Rothstein JD, Kuncl R, Chaundhry V et al. Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann Neurol 1991;30:224-5.
35. 35. Patten BM, Harati Y, Acosta L, Jung SS, Felmus MT. Free amino acid levels in amyotrophic lateral sclerosis. Ann Neurol 1978;3:305-9.
36. 36. Meier DH, Schott K-J. Free amino acid pattern of cerebrospinal fluid in amyotrophic lateral sclerosis. Acta Neurol Scand 1988;70:50-8.
37. 37. de Belleroche J, Recorgati A, Rose CF. Elevated levels of amino acids in the CSF of motor neuron disease patients. Neurochem Pathol 1984;2:1-6.
38. 38. Perry TL, Krieger C, Hansen S, Eisen A. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990;28:12-7.
39. 39. Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 1993;88:51-5.
40. 40. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid level in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4:209-16.
41. 41. Perry TL, Hansen S, Jones K. Brain glutamate deficiency in amyotrophic lateral sclerosis. Neurology 1987;37:1844-9.
42. 42. Yoshino K, Koike H, Akai K. Free amino acids in motor neuron cortex of amyotrophic lateral sclerosis. Experientia 1979;35:219-20.
43. 43. Robinson N. Chemical changes in the spinal cord in Friedreich's ataxia and motor neuron disease. J Neurol Neurosurg Psychiatry 1968;31:330-3.
44. 44. Tsia G, Stauch-Slusher B, Sim L et al. Reductions in acidic amino acids and N-acetyl-aspartyl-glutamate (NAAG) in amyotrophic lateral sclerosis CNS. Brain Res 1991;556:151-6.
45. 45. Plattakis A, Constantatakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988;24:446-9.
46. 46. Ono S, Yamamuchi M. Glutamate and aspartate are decreased in the skin in amyotrophic lateral sclerosis. Acta Neurol Scand 1992;86:481-4.
47. 47. Ziegler MG, Brooks BR, Lake CR, Wood JH, Enna SJ. Norepinephrine and gamma-amino-butyric acid in amyotrophic lateral sclerosis. Neurology 1980;30:98-101.
48. 48. Globus MY-T, Ginsberg MD, Busto R. Excitotoxic index a biochemical marker of selective vulnerability. Neurosci Lett 1991;127:39-42.
49. 49. Lakke JPWF, Teelken AW. Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders. Neurology 1976;26:489-95.
50. 50. Ferrarese C, Pecora N, Frigo M, Appollonio I, Frattola L. Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid. Ann Neurol 1993;33:316-19.
51. 51. Briddon A, Oberhozer VG. An alternative way of presenting quantitative amino acids results. Clin Chim Acta 1987;164:209-13.
52. 52. Lundquist C, Blomstrand C, Hamberger A, Wikkelso C. Liquid chromatographic separation of cerebrospinal fluid amino acids after precolumn fluorescence derivatization. Acta Neurol Scand 1989;79:273-9.